INOSITOL IN THE TREATMENT OF POLYCYSTIC OVARY SYNDROME: EVALUATION OF EFFICACY
DOI:
https://doi.org/10.47820/recima21.v5i9.5649Keywords:
myo-inositol. D-Chiro-Inositol. Menstrual cycle.Abstract
Polycystic Ovary Syndrome (PCOS) is a complex endocrine condition that affects many women of reproductive age, characterized by hormonal imbalances. Objective: to evaluate the efficacy of inositol in the treatment of polycystic ovary syndrome. Materials and methods: This is an integrative literature review, including research in the electronic database PubMed. The descriptors “Inositol", "Treatment", PCOS” and “polycystic ovary syndrome” were used to search for articles. The delimitation of the time frame of the research began in 2019. Since this is a study with a defined time limit, it was decided to restrict the search until July 2024. Ten articles were found to compose the review. Results and discussion: The available clinical data suggest that myo-inositol, D-chiro-inositol and their combination in the physiological ratio of 40:1 may be beneficial in improving the metabolic, hormonal and reproductive aspects of PCOS. In addition, isolated myo-inositol has also been shown to be effective in normalizing ovarian function, improving the quality of oocytes and embryos in polycystic ovary syndrome.
Downloads
References
DE SOUSA, Luís Manuel Mota et al. A metodologia de revisão integrativa da literatura em enfermagem. Revista investigação em enfermagem, v. 21, n. 2, p. 17-26, 2017.
DINICOLA, Simona et al. Inositols: from established knowledge to novel approaches. International Journal of Molecular Sciences, v. 22, n. 19, p. 10575, 2021. DOI: https://doi.org/10.3390/ijms221910575
ERCOLE, Flávia Falci; MELO, Laís Samara de; ALCOFORADO, Carla Lúcia Goulart Constant. Revisão integrativa versus revisão sistemática. Reme: Revista Mineira de Enfermagem, v. 18, n. 1, p. 09-11, 2014. DOI: https://doi.org/10.5935/1415-2762.20140001
FACCHINETTI, Fabio et al. Inositols in polycystic ovary syndrome: An overview on the advances. Trends in Endocrinology & Metabolism, v. 31, n. 6, p. 435-447, 2020. DOI: https://doi.org/10.1016/j.tem.2020.02.002
FITZ, Victoria et al. Inositol for Polycystic Ovary Syndrome: a systematic review and meta-analysis to inform the 2023 update of the International Evidence-Based PCOS Guidelines. The Journal of Clinical Endocrinology & Metabolism, v. 109, n. 6, p. 1630-1655, 2024.
GREFF, Dorina et al. Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Reproductive Biology and Endocrinology, v. 21, n. 1, p. 10, 2023. DOI: https://doi.org/10.1186/s12958-023-01055-z
KAMENOV, Zdravko; GATEVA, Antoaneta. Inositols in PCOS. Molecules, v. 25, n. 23, p. 5566, 2020. DOI: https://doi.org/10.3390/molecules25235566
LETE, Iñaki et al. Update on the combination of myo-inositol/d-chiro-inositol for the treatment of polycystic ovary syndrome. Gynecological Endocrinology, v. 40, n. 1, p. 2301554, 2024. DOI: https://doi.org/10.1080/09513590.2023.2301554
LI, Xiaofeng et al. The effect of metformin on homocysteine levels in patients with polycystic ovary syndrome: A systematic review and meta‐analysis. Journal of Obstetrics and Gynaecology Research, v. 47, n. 5, p. 1804-1816, 2021. DOI: https://doi.org/10.1111/jog.14725
MELLONIE, P. et al. The Effectiveness of Myo-Inositol in Women With Polycystic Ovary Syndrome: A Prospective Clinical Study. Cureus, v. 16, n. 2, 2024.
MENDES, Karina Dal Sasso; SILVEIRA, Renata Cristina de Campos Pereira; GALVÃO, Cristina Maria. Revisão integrativa: método de pesquisa para a incorporação de evidências na saúde e na enfermagem. Texto & contexto-enfermagem, v. 17, p. 758-764, 2008. DOI: https://doi.org/10.1590/S0104-07072008000400018
MERVIEL, Philippe et al. Impact of myo-inositol treatment in women with polycystic ovary syndrome in assisted reproductive technologies. Reproductive health, v. 18, p. 1-8, 2021. DOI: https://doi.org/10.1186/s12978-021-01073-3
NOTARO, Adriana Leal Griz; NETO, Filipe Tenorio Lira. The use of metformin in women with polycystic ovary syndrome: an updated review. Journal of Assisted Reproduction and Genetics, v. 39, n. 3, p. 573-579, 2022. DOI: https://doi.org/10.1007/s10815-022-02429-9
PUSTOTINA, Olga et al. The Effects of Myo-Inositol and D-Chiro-Inositol in a Ratio 40: 1 on Hormonal and Metabolic Profile in Women with Polycystic Ovary Syndrome Classified as Phenotype A by the Rotterdam Criteria and EMS-Type 1 by the EGOI Criteria. Gynecologic and Obstetric Investigation, v. 89, n. 2, p. 131-139, 2024. DOI: https://doi.org/10.1159/000536163
ROSEFF, Scott; MONTENEGRO, Marta. Inositol Treatment for PCOS Should Be Science‐Based and Not Arbitrary. International Journal of Endocrinology, v. 2020, n. 1, p. 6461254, 2020. DOI: https://doi.org/10.1155/2020/6461254
TEEDE, Helena J. et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Human reproduction, v. 33, n. 9, p. 1602-1618, 2018.
VYAS, Lila et al. Management of polycystic ovary syndrome among Indian women using myo‐inositol and D-chiro-inositol. Bioinformation, v. 18, n. 2, p. 103, 2022. DOI: https://doi.org/10.6026/97320630018103
WOJCIECHOWSKA, Anna et al. Inositols’ importance in the improvement of the endocrine–metabolic profile in PCOS. International journal of molecular sciences, v. 20, n. 22, p. 5787, 2019. DOI: https://doi.org/10.3390/ijms20225787
ZHANG, J.-Q.; XING, C.; HE, B. Short period-administration of myo-inositol and metformin on hormonal and glycolipid profiles in patients with polycystic ovary syndrome: a systematic review and updated meta-analysis of randomized controlled trials. European Review for Medical & Pharmacological Sciences, v. 26, n. 6, 2022.
Downloads
Published
License
Copyright (c) 2024 RECIMA21 - Revista Científica Multidisciplinar - ISSN 2675-6218
This work is licensed under a Creative Commons Attribution 4.0 International License.
Os direitos autorais dos artigos/resenhas/TCCs publicados pertecem à revista RECIMA21, e seguem o padrão Creative Commons (CC BY 4.0), permitindo a cópia ou reprodução, desde que cite a fonte e respeite os direitos dos autores e contenham menção aos mesmos nos créditos. Toda e qualquer obra publicada na revista, seu conteúdo é de responsabilidade dos autores, cabendo a RECIMA21 apenas ser o veículo de divulgação, seguindo os padrões nacionais e internacionais de publicação.
